Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update

Published on Jul 15, 2020in Hepatology Research3.165
· DOI :10.1111/HEPR.13504
Ryoichi Ando14
Estimated H-index: 14
,
Yasuhiro Asahina37
Estimated H-index: 37
+ 14 AuthorsHiroshi Yotsuyanagi41
Estimated H-index: 41
(UTokyo: University of Tokyo)
Sources
Abstract
The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug-resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.
📖 Papers frequently viewed together
6 Citations
10 Citations
References157
Newest
#1Marco PicardiH-Index: 35
#2Roberta Della PepaH-Index: 8
Last. Fabrizio PaneH-Index: 14
view all 13 authors...
TO THE EDITOR: The anti-CD20 monoclonal antibody rituximab, together with anthracycline, in hepatitis B surface antigen (HBsAg) healthy carriers affected by non-Hodgkin lymphoma (NHL) increases hepatitis B virus (HBV) reactivation risk.[1][1] Oral primary antiviral prophylaxis (PAVP) is a common
9 CitationsSource
#1Shigeru Kusumoto (Nagoya City University)H-Index: 25
#2Luca Arcaini (UNIPV: University of Pavia)H-Index: 65
Last. Kensei TobinaiH-Index: 65
view all 16 authors...
Risk of hepatitis B virus (HBV) reactivation was assessed in B-cell non-Hodgkin lymphoma (NHL) patients with resolved HBV infection (hepatitis B surface antigen negative, hepatitis B core antibody positive) who received obinutuzumab- or rituximab-containing immunochemotherapy in the phase 3 GOYA and GALLIUM studies. HBV DNA monitoring was undertaken monthly to 1 year after the last dose of study drug. In case of HBV reactivation (confirmed, HBV DNA ≥29 IU/mL), immunochemotherapy was withheld and...
47 CitationsSource
#1Akihiro Tamori (OCU: Osaka City University)H-Index: 39
#2S AbiruH-Index: 1
Last. Masashi MizokamiH-Index: 97
view all 13 authors...
: To determine the clinical characteristics of hepatitis B virus (HBV) reactivation in patients undergoing interferon-free antihepatitis C virus (HCV) therapy, we examined HBV DNA in 25 HBV co-infected patients and 765 patients with resolved HBV infection during and after treatment with direct-acting antiviral agents (DAAs). Among those with HCV genotype 1, asunaprevir plus daclatasvir was administered to 160 patients, sofosbuvir (SOF) plus ledipasvir to 438 patients and paritaprevir plus ombita...
22 CitationsSource
#1Kosh Agarwal (King's College)H-Index: 41
#2Maurizia Rossana Brunetto (UniPi: University of Pisa)H-Index: 67
Last. Henry Lik-Yuen Chan (CUHK: The Chinese University of Hong Kong)H-Index: 103
view all 29 authors...
Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes. In 48-week results from two ongoing, double-blind, randomized phase III trials, TAF was non-inferior to TDF in efficacy with improved renal and bone safety. We report 96-week outcomes for both trials. Methods In two international t...
142 CitationsSource
#1Kazuhiko Koike (UTokyo: University of Tokyo)H-Index: 91
#2Kazuaki Suyama (GSK: GlaxoSmithKline)H-Index: 6
Last. Wataru Sugiura (GSK: GlaxoSmithKline)H-Index: 2
view all 5 authors...
Aim The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) and entecavir hydrate (ETV) in nucleos(t)ide analog (NA)-naive Japanese chronic hepatitis B (CHB) patients. Methods This multicenter, randomized, double-blinded study assessing the efficacy and safety of TDF 300 mg and ETV 0.5 mg in NA-naive CHB subjects was carried out from November 2011 to November 2014, and funded by GlaxoSmithKline. The subjects were assigned to the TDF arm or ETV arm in a 2:1 rati...
39 CitationsSource
#1Eiichi Ogawa (Kyushu University)H-Index: 23
#2Norihiro Furusyo (Kyushu University)H-Index: 38
Last. Kazuya Ura (Kyushu University)H-Index: 6
view all 6 authors...
Background and Aims Despite a known risk of hepatitis B virus (HBV) reactivation during direct-acting antiviral (DAA) treatment for patients with hepatitis C virus (HCV)-HBV coinfection, it remains unclear whether patients with past HBV infection are at risk for reactivation. This study evaluated the risk of HBV reactivation during treatment with sofosbuvir (SOF)-based regimens, focusing on patients with resolved HBV infection. Methods This study analyzes the data of 183 consecutive patients tre...
25 CitationsSource
#1Hiromitsu KumadaH-Index: 89
#2Kazuhiko Koike (UTokyo: University of Tokyo)H-Index: 91
Last. Wataru Sugiura (GSK: GlaxoSmithKline)H-Index: 2
view all 6 authors...
Aim Acquisition of nucleos(t)ide analog (NA) inhibitor resistance is critical in successful chronic hepatitis B treatment. As the pattern of tenofovir disoproxil fumarate (TDF) resistance mutations differs from that of other antiviral drugs, we sought to clarify the salvaging potential of TDF in patients with hepatitis B virus (HBV) infection who are poor responders or resistant to other NAs. Methods A prospective, multicenter, single-arm, open-label study was carried out from December 2011 to O...
8 CitationsSource
#1Akira Doi (Osaka University)H-Index: 3
#2Ryotaro Sakamori (Osaka University)H-Index: 19
Last. Tetsuo Takehara (Osaka University)H-Index: 72
view all 15 authors...
Aim Several case reports have shown that hepatitis B virus (HBV) reactivation developed in hepatitis C patients with a current or previous HBV infection during direct-acting antiviral (DAA) treatment, which led to severe hepatitis or death in some cases. However, its precise frequency and risk factors are not entirely clear. We analyzed a prospective cohort. Methods We analyzed HBV reactivation in 461 consecutive hepatitis C patients who received 12 weeks of ledipasvir/sofosbuvir for genotype 1 ...
27 CitationsSource
#1Wataru FukudaH-Index: 8
#2Tadamasa HanyuH-Index: 2
Last. Shigeko InokumaH-Index: 20
view all 20 authors...
Background Although the reactivation of hepatitis B virus (HBV) is recognised as a serious complication in patients with rheumatic disease (RD) receiving immunosuppressive drugs (ISDs), the incidence and risk factors for reactivation remain controversial. Objectives To investigate the incidence and risk factors for HBV reactivation in patients with RD. Methods We performed a multicentre, observational, prospective study over 2 years in patients with resolved HBV infection. Patients with RD treat...
49 CitationsSource
#1Maria Buti (ISCIII: Carlos III Health Institute)H-Index: 80
#2Edward GaneH-Index: 66
Last. Patrick MarcellinH-Index: 131
view all 22 authors...
Summary Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic exposure. We compared the efficacy and safety of the two drugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-inferiority study. Methods In this ongoing randomised, double-blind, phase 3, non-inferiority study in 105 centres in ...
249 CitationsSource
Cited By14
Newest
#1Daiki YamashigeH-Index: 1
#2Tetsuya HosakaH-Index: 55
Last. Satoshi SaitohH-Index: 61
view all 14 authors...
Few studies have demonstrated the potency of tenofovir alafenamide (TAF) in patients with poor response to other nucleos(t)ide analogs (NAs). We conducted a retrospective study comprising consecutive 40 patients exhibiting a poor response to other NAs, who subsequently received TAF-containing regimens. The primary outcome was the prevalence of virological response (VR) at each time and maintained virological response (MVR) under TAF-containing regimens until week 96. In the entire cohort, the pr...
Source
#1Masataka Tsuge (Hiroshima University)H-Index: 34
Chronic hepatitis B virus (HBV) infection is a worldwide health problem leading to severe liver dysfunction, including liver cirrhosis and hepatocellular carcinoma. Although current antiviral therapies for chronic HBV infection have been improved and can lead to a strong suppression of viral replication, it is difficult to completely eliminate the virus with these therapies once chronic HBV infection is established in the host. Furthermore, chronic HBV infection alters intracellular metabolism a...
Source
#1Hiroki NishikawaH-Index: 23
#2Kazunori YohH-Index: 16
Last. Hiroko IijimaH-Index: 28
view all 5 authors...
We aimed to examine the association between sarcopenia-related factors and metabolic syndrome (Met-S) in patients with chronic liver diseases (CLDs, n = 582, average age = 59.5 years, 290 males, 168 liver cirrhosis cases). Met-S was determined based on the Japanese criteria. Sarcopenia was determined based on grip strength (GS) and skeletal muscle index (SMI) by bioelectrical impedance analysis. Our cohort was divided into the four groups: (A) sarcopenia (n = 44), (B) dynapenia (n = 45), (C) pre...
Source
#1Masaru Enomoto (OCU: Osaka City University)H-Index: 28
#2Takeji Umemura (Shinshu University)H-Index: 40
Last. Fumitaka SuzukiH-Index: 3
view all 3 authors...
1 CitationsSource
#1Hitoshi Yonezawa (Sapporo Medical University)H-Index: 1
#2Shingo Tanaka (Sapporo Medical University)H-Index: 9
Last. Junji Kato (Sapporo Medical University)H-Index: 40
view all 9 authors...
Abstract null null Introduction null In quantitative assays for hepatitis B virus (HBV) DNA, although the amplification reaction signal is detected for low-positive cases, quantification remains challenging. HBV reactivation has been reported in many studies, but only a few have focused on HBV low-positive cases. This study aimed to determine the reactivation rate and risk factors for HBV reactivation in low-positive cases. null null null Methods null In this retrospective cohort study, we analy...
Source
BACKGROUND/AIM The serum hepatitis B core-related antigen (HBcrAg) is considered a surrogate marker of the amount and activity of intrahepatic covalently closed circular (ccc) DNA. This study aims to investigate the virological characteristics of HBcrAg in chronic hepatitis B (CHB) patients and to reveal the hepatocellular carcinoma (HCC) HCC risk factors of HBeAg-negative patients. METHODS HBcrAg was measured in 245 naive CHB patients before receiving Nucleoside/nucleotide analogs (NA) therapy....
Source
INTRODUCTION Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. METHODS ETV-treated (≥12 months) chronic hepatitis B patients switched to TAF in routine practice at 15 centers (United States, Korea, Japan, and Taiwan) were included. Primary outcome was complete viral suppression (CVS) rate (HBV DNA <20 IU/mL). RESULTS We analyzed ...
Source
#1Satoshi TakakusagiH-Index: 3
#2Hitoshi TakagiH-Index: 32
Last. Hiroaki Okamoto (Jichi Medical University)H-Index: 113
view all 10 authors...
A 76-year-old woman with spontaneous reactivation of hepatitis B virus (HBV) without any immunosuppressants who had been successfully treated with tenofovir alafenamide fumarate (TAF) was reported. The patient was admitted to our hospital because of acute exacerbation of the liver function and jaundice. She had been found to have chronic HBV infection with a normal liver function and had been treated for lifestyle-related diseases, such as diabetes mellitus, dyslipidemia and hypertension, for ov...
Source
#1Hye Won Lee (Yonsei University)H-Index: 22
#2Sang Hoon Ahn (Yonsei University)H-Index: 69
Last. Henry Lik-Yuen Chan (CUHK: The Chinese University of Hong Kong)H-Index: 103
view all 3 authors...
Hepatitis B core-related antigen (HBcrAg) is a composite measure of the serum levels of hepatitis B e antigen, hepatitis B core antigen, and a 22-kDa precore protein. It has been shown to reflect the level and transcriptional activity of covalently closed circular DNA in the liver. Longitudinal cohort studies have improved our understanding of the role of this novel viral marker in the natural history of chronic hepatitis B. HBcrAg kinetics reflect the response to peginterferon, and its role in ...
Source
#1Kanako Yoshida (OCU: Osaka City University)H-Index: 3
#2Masaru Enomoto (OCU: Osaka City University)H-Index: 28
Last. Norifumi Kawada (OCU: Osaka City University)H-Index: 66
view all 5 authors...
Seroclearance of hepatitis B surface antigen (HBsAg) ("functional cure") is the optimal endpoint of antiviral therapy for chronic hepatitis B virus (HBV) infection. Currently available anti-HBV therapy includes nucleoside/nucleotide analogs (NAs) and peginterferon-α (Peg-IFNα). Combination of NAs and Peg-IFNα, each with different mechanisms of action, is an attractive approach for treating chronic HBV infection. In earlier studies, compared with monotherapy using IFNα, combination therapy showed...
1 CitationsSource